| Hu, Chaur-Jong |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT04097652: Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 9 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/23 | 12/25 | | |
| Chan, Lung |
NCT04097652: Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 9 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/23 | 12/25 | | |
NCT04914403: Mesenchymal Stem Cells for The Treatment of Frailty Syndrome |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05 | Meridigen Biotech Co., Ltd. | Frailty Syndrome | 12/24 | 07/25 | | |
| Liou, Tsan-hon |
NCT04914403: Mesenchymal Stem Cells for The Treatment of Frailty Syndrome |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05 | Meridigen Biotech Co., Ltd. | Frailty Syndrome | 12/24 | 07/25 | | |
| Lee, Kang-Yun |
| Completed | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294, Depemokimab, Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
|
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
|
|
| Active, not recruiting | 3 | 641 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 05/25 | 05/25 | | |
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 950 | Canada, US, RoW | fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo | Regeneron Pharmaceuticals | Non-small Cell Lung Cancer | 01/30 | 12/31 | | |
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2/3 | 850 | Canada, US, RoW | fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo | Regeneron Pharmaceuticals | Advanced Non-Small Cell Lung Cancer | 03/30 | 02/32 | | |
|
NCT05008965: Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
|
|
| Recruiting | 2 | 100 | RoW | FB825, Placebo | Oneness Biotech Co., Ltd., Microbio Shanghai Co., Ltd. | Allergic Asthma | 06/24 | 06/24 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
NCT06415487: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) |
|
|
| Recruiting | 1 | 30 | US, RoW | Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab | Acepodia Biotech, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 12/26 | 03/27 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
NCT04909034: A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer |
|
|
| Completed | N/A | 15 | RoW | MS-20, Chemo young, Placebo | Microbio Co Ltd | NSCLC Stage IIIB~IV | 10/24 | 11/24 | | |
| Huang, Shih-Wei |
NCT04914403: Mesenchymal Stem Cells for The Treatment of Frailty Syndrome |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05 | Meridigen Biotech Co., Ltd. | Frailty Syndrome | 12/24 | 07/25 | | |
| Chen, Kuan-Yuan |
NCT05941793: A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients |
|
|
| Completed | 2 | 135 | US, RoW | MBS-COV, Placebo | Oneness Biotech Co., Ltd. | Mild to Moderate COVID-19 | 08/24 | 08/24 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Chen, Tzu-Tao |
NCT05018299: Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma |
|
|
| Recruiting | 2 | 40 | RoW | FB704A placebo, FB704A | Oneness Biotech Co., Ltd. | Severe Asthma | 09/25 | 09/25 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Tseng, Yen-Han |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Tseng, Chien-Hua |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Feng, Po-Hao |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
TRIO, NCT05557487: Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration |
|
|
| Recruiting | N/A | 6618 | RoW | Low dose computed tomography | Gee-Chen Chang, AstraZeneca | Lung Cancer, High-Risk Cancer, Smoking, Pollution; Exposure, Family Relations | 12/24 | 12/28 | | |
| Liu, Wen-Te |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Luo, Ching-Shan |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Yeh, Yun-Kai |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Li, Mandy |
NCT04097652: Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 9 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/23 | 12/25 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Chen, Hung-Chou |
NCT04914403: Mesenchymal Stem Cells for The Treatment of Frailty Syndrome |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05 | Meridigen Biotech Co., Ltd. | Frailty Syndrome | 12/24 | 07/25 | | |
| Liao, Mya |
NCT04914403: Mesenchymal Stem Cells for The Treatment of Frailty Syndrome |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05 | Meridigen Biotech Co., Ltd. | Frailty Syndrome | 12/24 | 07/25 | | |
| Liao, Claire |
NCT04097652: Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 9 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/23 | 12/25 | | |
NCT04893174: Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA). |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05, Hyaluronic acid | Meridigen Biotech Co., Ltd. | Osteoarthritis, Knee | 09/24 | 06/25 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
NCT04914403: Mesenchymal Stem Cells for The Treatment of Frailty Syndrome |
|
|
| Recruiting | 1 | 6 | RoW | UMC119-06-05 | Meridigen Biotech Co., Ltd. | Frailty Syndrome | 12/24 | 07/25 | | |
NCT03631420: Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants |
|
|
| Recruiting | 1 | 9 | RoW | Human Umbilical Cord Derived-Mesenchymal Stem Cells | Meridigen Biotech Co., Ltd. | Bronchopulmonary Dysplasia | 12/25 | 07/27 | | |
